Rhythm Pharmaceuticals

Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Their lead peptide product candidate, setmelanotide, is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of rare genetic disorders of obesity. They believe that setmelanotide, for which they have exclusive worldwide rights, has the potential to serve as replacement therapy for the treatment of melanocortin 4, or MC4, pathway deficiencies. The MC4 pathway is a compelling target for treating these genetic disorders because of its critical role in regulating appetite and weight, and peptide therapeutics are uniquely suited to activating this target.

Rhythm Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Pharmaceutical, Therapeutics sector. The company focuses on Biotechnology and has secured $138.0B in funding across 132 round(s). With a team of 101-250 employees, Rhythm Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Rhythm Pharmaceuticals, raised $41.0M. Discover more about their projects, partnerships, and impact on our platform.